aDepartment of Pediatrics, Division of Pediatric Infectious Disease, University of Washington and Seattle Children's Research Institute, Seattle, WA;
bMerck & Co., Inc., Rahway, NJ;
cHarvard T.H. Chan School of Public Health, Boston, MA;
dFrontier Science Technology and Research Foundation, Brookline, MA;
eDepartment of Pediatrics, Division of Pediatric Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA;
fFHI 360, Durham, NC;
gResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand;
hChiangrai Prachanukroh Hospital PHPT, Chiang Rai, Thailand;
iFaculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand;
jPHRU, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa;
kDepartment of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Denver, CO;
lDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN;
mBoston Medical Center, Boston University School of Medicine, Boston, MA;
nFrontier Science, Amherst, NY;
oDAIDS/NIAID/NIH, Rockville, MD;
pNICHD/NIH, Bethesda, MD; and
qSkaggs School of Pharmacy and Pharmaceutical Sciences and Pediatrics Department, School of Medicine-Rady Children's Hospital San Diego, University of California San Diego, San Diego, CA.
Correspondence to: Ann J. Melvin M.D., M.P.H., Seattle Children's Hospital, Division of Pediatric Infectious Disease, 4800 Sandpoint Way NE, MA.7.226, Seattle, WA 98105 (e-mail: [email protected]).
Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC), and UM1AI106716 (IMPAACT LC), and by NICHD Contract Number HHSN275201800001I. Financial support and antiretrovirals (DOR and DOR/3TC/TDF) were provided by Merck & Co., Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
K.L.Y., H.W., H.T. (now retired), and H.C. hold stock and are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD) [license holder Pifeltro and Delstrigo]. P.F. participates on a Merck safety monitoring committee for non-HIV drugs. For the remaining authors, no conflicts of interest were disclosed.
Presented at 11th International Workshop on HIV & Pediatrics 2019, Mexico City, Mexico, July 19–20. Poster# 39 and conference on Retrovirology and Opportunistic Infections, 2021, Virtual Conference March 6-10.
K.P.G.'s current affiliation is Boston Children's Hospital, Boston, MA, and Harvard Medical School, Cambridge, MA, USA; M.Y.'s current affiliation is Labcorp Drug Development Inc., Durham, NC, USA; and H.T. is currently retired.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).
